Activotec is part of an exciting collaboration called Coronex to develop a game-changing platform for lateral flow (LF) tests that could be vital in the fight against COVID-19.
This proprietary platform technology has been used to develop highly optimised LF tests for SARS-Cov-2 antibodies. The technology also allows LF tests to be adapted easily and rapidly to detect antibodies to newly isolated variants when mutation arise.
Coronex’s technological advancements optimise the mechanism by which the COVID-19 antibodies are detected in the LF test, thereby minimising ambiguous or inaccurate results whilst also allowing the target antigen to be easily changed.
This means the test kits offer clearer, more accurate results, are easily altered to adapt to virus mutations and are cheaper to manufacture. The technology has been developed and tested over six months on a cohort of COVID-19 samples provided by the NHS Greater Glasgow and Clyde Biorepository Network.
Coronex is now seeking an investment partner to support further development and validation, to bring this innovative test into early clinical use and extend the technology to other diagnostic areas.
Chris Littlewood, CEO of Activotec Ltd, based in Cambridge comments:
“We are in no doubt that the Coronex platform has re-engineered and revolutionised lateral flow technology. The adaptability of the technology is vitally important when we see the rapid spread of the new coronavirus variants; and whilst our primary focus has been on SARS-CoV-2, the same core technology could have applications for other infectious agents, or in detecting auto-antibodies in autoimmune disorders or monitoring therapeutic antibodies used as drug treatments. We have proven the technology works and with further investment can accelerate translation into widespread clinical use.”
Contact Activotec CEO, Chris Littlewood for more information.
“Our unique lateral flow design has several innovative features that will produce a more accurate test than traditional designs, and can be rapidly adapted to viral mutations.”
— Dr John Goodfellow, Consultant Neuroimmunologist and Clinical Director of the Neuroimmunology Laboratory at the Queen Elizabeth University Hospital, Glasgow